Alloy Therapeutics, a biotechnology ecosystem company, announced the close of a $75 million Series C financing round. The round was led by 8VC, Presight Capital, and Peter Thiel with participation from new investors including Mubadala Capital, the asset management arm of Mubadala Investment Company; an unnamed sovereign wealth fund; Founders Fund and Gaingels; as well as Alloy's existing investors Luma Bio-IT, Alexandria Venture Investments, and Ulysses Diversified Holdings.

Founded in 2017, Alloy Therapeutics is a biotechnology ecosystem company empowering the global scientific community to make better medicines together. Through a community of partners, Alloy democratizes access to tools, technologies, services, and company creation capabilities that are foundational for discovering and developing therapeutic biologics. The company facilitates affordable, non-exclusive access to the entire drug discovery community from academic scientists, small and medium biotech, to the largest biopharma. Alloy's lead offering, the ATX-Gx platform, is a human therapeutic antibody discovery platform consisting of a growing suite of proprietary transgenic mice strains.